We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Uniqure Nv | LSE:0EE0 | London | Ordinary Share | NL0010696654 | UNIQURE ORD SHS |
| Price Change | % Change | Share Price | Bid Price | Offer Price | |
|---|---|---|---|---|---|
| 0.00 | 0.00% | 31.50 |
| High Price | Low Price | Open Price | Shares Traded | Last Trade |
|---|---|---|---|---|
| 6,154 | 00:00:00 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Pharmaceutical Preparations | 21.9M | -308.48M | -6.4489 | -2.50 | 1.51B |
| Date | Time | Source | Headline |
|---|---|---|---|
| 03/2/2025 | 12:05 | UKREG | uniQure Announces Completion of Enrollment in the First Cohort and.. |
| 30/1/2025 | 12:37 | UKREG | uniQure Announces Favorable Recommendation from Independent Data Monitoring.. |
| 08/1/2025 | 12:05 | UKREG | uniQure Announces Pricing of its Public Offering |
| 07/1/2025 | 21:49 | UKREG | uniQure Announces Proposed Public Offering |
| 10/12/2024 | 12:05 | UKREG | uniQure Announces Alignment with FDA on Key Elements of Accelerated.. |
| 21/11/2024 | 12:05 | UKREG | uniQure Announces Dosing of First Patient in GenTLE Phase I/IIa Clinical.. |
| 05/11/2024 | 12:05 | UKREG | uniQure Announces Third Quarter 2024 Financial Results and Highlights.. |
| 15/10/2024 | 11:05 | UKREG | uniQure Announces Dosing of First Patient in Phase I/II Clinical Trial of.. |
| 23/9/2024 | 11:05 | UKREG | uniQure Announces Orphan Drug Designation Granted to AMT-191 for the.. |
| 15/8/2024 | 11:05 | UKREG | uniQure Announces Dosing of First Patient in Phase I/IIa Clinical Trial of.. |
1 Year Uniqure Nv Chart |
Intraday Uniqure Nv Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
